Business
AstraZeneca advances response to COVID-19 outbreak
AstraZeneca advances response to COVID-19 outbreak.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n RNS Number : 5972N\n AstraZeneca PLC\n 21 May 2020\n \n \n \n This announcement contains inside information\n \n 21 May 2020 07:00 BST\n \n \n AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine \n \n \n \n Company working on a number of agreements in parallel to ensure broad and equitable supply of the vaccine throughout the world at no profit during the pandemic\n \n \n \n \n \n First agreements to supply at least 400 million doses; Company has total capacity sourced for one billion doses through 2020 and into 2021; continues to increase capacity further\n \n \n \n \n \n More than $1bn US BARDA investment to support\ndevelopment and production of the vaccine\n \n \n AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford's vaccine widely accessible around the world in an equitable manner.\n \n The Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020. AstraZeneca aims to conclude further agreements supported by several parallel supply chains, which will expand capacity further over the next months to ensure the delivery of a globally accessible vaccine. \n \n AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall. The development programme includes a Phase III clinical trial with 30,000 participants and a paediatric trial.\n \n In addition, the Company is engaging with international organisations such as the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance and the World Health Organisation (WHO), for the fair allocation and distribution of the vaccine around the world. AstraZeneca is also in discussions with governments around the world to increase access. Furthermore, AstraZeneca is in discussions with the Serum Institute of India and other potential partners to increase production and distribution.\n ...